author-photo

Corinne Haioun

University of Paris
French Institute of Health and Medical Research
Paris 12 Val de Marne University

541

Papers

23698

Citations

Citation Trend

Filter By

Papers (541) Sort By

Journal Conference Others

Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study

2021 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Development of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study

2021 International Journal of Environmental Research and Public Health
Show All
- Source
- Cite
- Save
Citations (0)
CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
GENDER DISPARITIES IN QUALITY OF LIFE OF FRENCH PATIENTS ONE YEAR AFTER THE DIAGNOSIS OF LYMPHOMA. A LYSA STUDY

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (1)
BASELINE CIRCULATING TUMOUR DNA AND TOTAL METABOLIC TUMOUR VOLUME AS EARLY OUTCOME PREDICTORS IN AGGRESSIVE B‐CELL LYMPHOMA. A REAL LIFE PROSPECTIVE 112‐PATIENT COHORT

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)